Clinical Trial Update: Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating first-line pembrolizumab in combination with lenvatinib for urothelial carcinoma in cisplatin-ineligible or platinum-ineligible patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Urothelial Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2023-10-31